Zydus Lifesciences moves up as its arm, Daewoong Pharmaceutical enter into exclusive licensing agreement

12 Dec 2023 Evaluate

Zydus Lifesciences is currently trading at Rs. 635.80, up by 2.60 points or 0.41% from its previous closing of Rs. 633.20 on the BSE.

The scrip opened at Rs. 637.50 and has touched a high and low of Rs. 640.40 and Rs. 633.60 respectively. So far 7353 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022.

Last one week high and low of the scrip stood at Rs. 664.00 and Rs. 631.10 respectively. The current market cap of the company is Rs. 64340.76 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.95% and 7.07% respectively.

Zydus Lifesciences’ wholly owned subsidiary -- Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., have entered into an exclusive licensing agreement to co-develop and commercialize Leuprolide Acetate for Depot Suspension (RLD: Lupron Depot, AbbVie) in six dosage strengths for the United States market.

Under the terms of the agreement, Zydus will assume full responsibility for the clinical development and commercialization in the US market, and Daewoong will be responsible for the pre-clinical studies, production and supply of the product. Daewoong, utilizing its proprietary technology, will produce Leuprolide Acetate for Depot Suspension in its manufacturing facilities located in Osong, South Korea. The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome. Additionally, this agreement also includes a profit share on future sales between the two companies.

By combining the unique strengths and expertise of both companies to develop and commercialize Leuprolide Acetate for Depot Suspension, Zydus and Daewoong are set to make a positive impact in the healthcare industry, ensuring accessibility, affordability, and enhanced patient empowerment. 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×